MetaVia Reports Significant Phase 2a Findings for Vanoglipel in MASH Patients at AASLD 2025 MetaVia Inc. highlights promising Phase 2a data on vanoglipel, showcasing its efficacy in treating patients with presumed MASH during the AASLD Liver Meeting 2025.

MetaVia Reports Significant Phase 2a Findings for Vanoglipel in MASH Patients at AASLD 2025 #United_States #Washington_D.C. #MetaVia #Vanoglipel #Phase_2a_Data